Refractory cancer
Clinical trials for Refractory cancer explained in plain language.
Never miss a new study
Get alerted when new Refractory cancer trials appear
Sign up with your email to follow new studies for Refractory cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new antibody help the immune system fight Hard-to-Treat tumors?
Disease control CompletedThis trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…
Matched conditions: REFRACTORY CANCER
Phase 1/2 • Sponsor: Sensei Biotherapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo therapy shows promise for hard-to-treat childhood cancers
Disease control CompletedThis early-stage study tested a mix of two drugs (pembrolizumab and decitabine) plus targeted radiation in 22 children and young adults whose solid tumors or lymphoma had returned or stopped responding to treatment. The main goals were to see if the combination was safe and toler…
Matched conditions: REFRACTORY CANCER
Early phase 1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Lab tests aim to tailor cancer treatments for patients who've run out of options
Knowledge-focused CompletedThis study tests whether doctors can quickly recommend personalized cancer treatments for adults whose cancers have returned or stopped responding to standard therapy. Researchers will take a sample of the tumor, test it against many drugs in the lab, and also analyze its genes. …
Matched conditions: REFRACTORY CANCER
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Gene-Guided cancer therapy put to the test in 742 patients
Knowledge-focused CompletedThis study tested whether choosing cancer drugs based on the genetic makeup of a patient's tumor works better than standard treatment. It included 742 adults with advanced solid tumors that had stopped responding to usual therapies. Patients were randomly assigned to receive eith…
Matched conditions: REFRACTORY CANCER
Phase 2 • Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC